At a Glance
- Goal is to deliver a protein therapy locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy
- Arthritis is leading cause of disability in the U.S. affecting > 52 million adults and 300,000 children1
- Collaboration combines Fibrocell’s expertise in autologous fibroblast technology with Intrexon’s cellular engineering to develop localized, engineered cell-based therapies
1Centers for Disease Control and Prevention: http://www.cdc.gov/chronicdisease/resources/publications/aag/arthritis.htm. Accessed 01.18.16.